Navigation Links
Nitec Pharma Expands Senior Management Team
Date:10/4/2007

hering Plough Research Institute, where he was responsible for developing and implementing new processes for enhancing strategic commercial input into the drug-development process. He retired from SP in 2004. At Nitec Pharma, Mr. Audibert's primary responsibility is strategic development and partnering for the US market, as well as assisting the founders in overall product development and commercial strategies. He holds a BS in Pharmacy and MS in Pharmacology from Northeastern University in Boston, MA.

About Nitec Pharma AG:

Nitec Pharma is a biopharmaceutical company specialized in the development and commercialization of optimized medicines for the treatment of chronic inflammatory diseases and pain. Nitec is headquartered in Reinach, Switzerland, with a subsidiary in Mannheim, Germany. The Company's most advanced product is LodotraTM, a circadian cytokine modulator (CCMTM) based on a night time release formulation of prednisone, for the treatment of rheumatoid arthritis (RA) -addressing in particular the morning stiffness characteristic of RA. LodotraTM has successfully completed Phase III clinical trials and will also be developed for other inflammatory diseases. Nitec was originally founded in 2004 as a spin-out of Merck KGaA. The Company is financed by Atlas Venture, Global Life Science Ventures and NGN Capital. For further information about Nitec Pharma please visit http://www.nitecpharma.com

This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties rea
'/>"/>

SOURCE Nitec Pharma AG
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Promega and Benitec settle contract case
2. Analyzing Trace-Level Impurities of a Pharmaceutical Intermediate Using an LCQ Deca Ion Trap Mass Spectrometer and the Mass Frontier Software Package
3. Rapid SNP Genotyping of the Pharmacogenomically Important Allele CYP2D6*4 Using Real-Time qPCR on the DNA Engine Opticon 2 System
4. Development of a sensitive enzyme fragment complementation assay for cyclic adenosine 3, 5 monophosphate and its validation for pharmacological screening at G protein-coupled receptors
5. Practical Applications of HyperDSC in a Pharmaceutical Laboratory
6. World Class Life Science and Pharmaceutical Companies Leverage DoveBid s Global Reach for Asset Management and Disposition
7. Germantown drug company hires pharma veteran James Davidson as COO
8. Deltanoid Pharmaceuticals begins phase II osteoporosis study
9. New angel capital centered on GenTel agreement with big pharma
10. The deconstruction of Big Pharma
11. Big pharma seeks Wisconsin biotech partnerships
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 30, 2015 AACC welcomed thousands of ... AACC Annual Meeting & Clinical Lab Expo in ... The meeting showcased revolutionary advancements in clinical testing ... healthcare providers to diagnose patients quickly and accurately ... As of Wednesday, July 29, ...
(Date:7/30/2015)... ... , ... The 2015 Market Research Report on the Global Propanol Industry ... Propanol market with a focus on the Chinese situation. Major companies included in the ... Chemical, Sanofi, Royal Dutch Shell, LG Chem and Zhejiang Xinhua Chemical. , The report ...
(Date:7/30/2015)... CITY, Kan. , July 30, 2015 /PRNewswire/ ... ), a pet therapeutics company focused on the ... for companion animals, today announced that its strategic ... from a dose confirmation study of AT-016, an ... Aratana for the treatment of osteoarthritis pain in ...
(Date:7/30/2015)... COPENHAGEN, Denmark , July 30, 2015 /PRNewswire/ ... a biotechnology company that applies its innovative TransCon ... announced positive top-line results from a six-month Phase ... of once-weekly TransCon Growth Hormone in 53 treatment-naïve, ... "We are extremely pleased with the ...
Breaking Biology Technology:Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4Global Propanol Market Technical Data and Manufacturing Analysis 2020 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7
... 2011 Today, the Access Group--a leading health care ... of 2 business entities, Promidian and Strategic Selling Solutions ... leaders. The Access Group was formed ... life sciences industries to provide full-service strategy and communications ...
... Diagnostics Incorporated (NYSE: DGX ), the world,s ... test has been approved by New York State,s Department ... state. It is believed to be the first molecular ... to be approved by the state.   ...
... March 17, 2011 Delta Point, Inc., a consulting ... business relationships, has named Ed Weimer as Executive Account ... for his ability to highly motivate, develop and inspire ... strategic vision to contribute to the organization,s goals. ...
Cached Biology Technology:Introducing the Access Group and Its New Business Entities 2Introducing the Access Group and Its New Business Entities 3Introducing the Access Group and Its New Business Entities 4Introducing the Access Group and Its New Business Entities 5Introducing the Access Group and Its New Business Entities 6New York State Approves the Quest Diagnostics ColoVantage™ Colorectal Cancer Blood Test 2New York State Approves the Quest Diagnostics ColoVantage™ Colorectal Cancer Blood Test 3Ed Weimer Joins Delta Point, Inc. as Executive Account Director 2
(Date:7/30/2015)... MOUNTAIN VIEW, Calif. , July 30, 2015 ... products and services for gene function analysis and ... CRISPR Guide RNA (sgRNA) Knockout Library targeting all ... to specifically and permanently "knock out" a gene,s ... library provides a high throughput screening tool so ...
(Date:7/27/2015)... 27, 2015   Zynx Health ™, the ... improvement solutions, today announced that its ZynxCarebook ... on Android smartphones and tablets. With this expansion, ... can use ZynxCarebook to securely exchange messages and ... care transitions to other care settings, and improve ...
(Date:7/23/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/rzzp3v/global_outlook_of ... "Global Outlook of the Biometrics Industry 2015 " ... The global biometrics market is likely to witness ... owing to the uptake of multiple technologies available. ... enhances the growth of biometrics in existing applications ...
Breaking Biology News(10 mins):CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3Global Outlook of the Biometrics Industry 2015 2Global Outlook of the Biometrics Industry 2015 3
... that animals living at high latitudes grow better than ... is more nutritious. The study, published in the February ... novel explanation for Bergmann,s Rule, the observation that animals ... Ever since Christian Bergmann made his observation about latitude ...
... available in Spanish . , Pistachios, almonds and ... a yeast called Pichia anomala . Laboratory and ... (Sylvia) Hua have shown that the yeast competes successfully for ... unwanted mold, Aspergillus flavus . A. ...
... Figs and fig wasps have evolved to help each other ... wasp larvae can safely develop, and in return, the wasps pollinate ... eggs but fails to pollinate the fig? The trees get ... wasps inside, reports a Cornell University and Smithsonian Tropical Research Institute ...
Cached Biology News:Better food makes high-latitude animals bigger 2Trees retaliate when their fig wasps don't service them 2
APO-BrdU™ TUNEL Assay Kit *with Alexa Fluor® 488 anti-BrdU* *60 assays*...
...
IMAGEQUANT 300 IQTL, 1 EA. Category: ImageQuant CCD Imagers....
RayBio Human Cytokine Antibody Array 1.1 (4 array membranes) with Accessory, detects 20 cytokines (for lysate) Class: Antibody Array Products Product Group: Antibody Array...
Biology Products: